Background: We sought to evaluate the effects of aortic annulus size on valve hemodynamics and clinical outcomes in those patients included in the PARTNER randomized controlled trial (RCT) cohort A and the PARTNER non-randomized continued access (NRCA) cohort. Methods: Patients included the RCT (n¼574) and NRCA (n¼1358) cohorts were divided in tertiles according to aortic annulus diameter (small, medium, large aortic annulus; SAA, MAA and LAA, respectively) as measured by transthoracic echocardiography. Moderate-to-severe prosthesis-patient mismatch (PPM) was defined as an effective aortic orifice area of 0.85 cm2/m2. Results: In the RCT cohort, patients in the SAA tertile who underwent TAVR had a lower incidence of PPM (39% vs. 63%, P¼0.01), and only a trend toward a higher incidence of moderate-to-severe paravalvular leak (PVL) compared to SAVR (5.7% vs. 0%, P¼0.06). In the LAA tertile, there were no differences in the rate of PPM between groups and a significant increase in moderate-to-severe PVL was associated with TAVR (9% vs. 0%, P¼0.01). In the NRCA cohort, there were no differences in PPM between the SAA and LAA tertiles, but a higher rate of moderate-to-severe PVL was observed in the LAA tertile (5.9% vs. 11.5%, P¼0.004). Patients in the LAA tertile had a higher mortality rate at 1-year follow-up compared to the SAA and MAA tertiles (24.8%, 18.3% and 18.7%, respectively, P¼0.02), and differences persisted in multivariable analysis (P¼0.048 for LAA vs. MAA, P¼0.035 for LAA vs. SAA). Conclusions: Aortic annulus size had a major impact on valve hemodynamics and clinical outcomes following AVR. This study highlights the importance of considering aortic annulus size in the evaluation of high-risk patients who are candidates for AVR, and suggests that TAVR may be the preferred strategy for those with smaller aortic annulus. Background: Transcatheter aortic valve-in-valve (VinV) implantation inside failed bioprostheses is increasingly being performed. Stentless surgical valves lack fluoroscopic markers and may pose unique challenges. We aimed to evaluate clinical outcomes following aortic VinV procedures in stentless bioprostheses, using a large global registry. Methods: Aortic VinV procedures included in the Global Valve-in-Valve Registry were investigated (553 procedures: 441 in stented bioprostheses, 112 stentless). Results: Patients with failed stentless bioprostheses were younger and had similar STS score in comparison with those with stented (73.4 AE 13.9 vs. 78.6 AE 8, p< 0.001; 10.7 AE 8.3 vs. 12.1 AE 10.6, p¼0.20, respectively). Stentless bioprostheses had a longer median time to failure and failed more commonly with predominant regurgitation (11 vs. 9 years, p¼0.02 and 58.9% vs. 21.8% in stented, p< 0.001), were larger (23.8 AE 2.1 vs. 23.0 AE 2.1 in stented, p¼0.002) and had lower degree of stenosis in comparison with stented: valve area 1.28 AE 0.62cm2 vs. 0.88 AE 0.43cm2, mean gradient 48 AE 28.6 mmHg vs. 64.7 AE 26.8mmHg, respectively; p< 0.001 for both). Stentless bioprostheses were more commonly treated by a CoreValve (65.1% vs. 34.7% SAPIEN, p< 0.001) and TEE was utilized more during these procedures (75.2% vs. 62.6% in stented, p¼0.01). Device malposition was more common in stentless and Mosaic stented valves (16.1%, 14.0% vs. 9.0% in non-Mosaic stented valves, p¼0.03). Coronary occlusion was more common in stentless bioprostheses (5.4% vs. 1.4% in stented, respectively, p¼0.01). Post procedural mean aortic valve gradient was lower post stentless VinV procedures (11.7 AE 7.2mmHg vs. 16.9 AE 9.1mmHg in stented, p< 0.001). Thirty-day and 1-year mortality rates were similar, when comparing stented and stentless procedures: 8.9% vs.6.6% (p¼0.39), 17.9% vs. 16.6% (p¼0.68), respectively. Conclusions: Aortic VinV implantation inside stentless bioprosthesis is challenging and associated with more device malposition and coronary occlusion events. Nevertheless, VinV procedures performed in stentless bioprostheses resulted better valve hemodynamics than in stented surgical valves and patient survival was similar.
Background: Transcatheter aortic valve-in-valve (VinV) implantation inside failed bioprostheses is increasingly being performed. Stentless surgical valves lack fluoroscopic markers and may pose unique challenges. We aimed to evaluate clinical outcomes following aortic VinV procedures in stentless bioprostheses, using a large global registry. Methods: Aortic VinV procedures included in the Global Valve-in-Valve Registry were investigated (553 procedures: 441 in stented bioprostheses, 112 stentless). Results: Patients with failed stentless bioprostheses were younger and had similar STS score in comparison with those with stented (73.4 AE 13.9 vs. 78.6 AE 8, p< 0.001; 10.7 AE 8.3 vs. 12.1 AE 10.6, p¼0.20, respectively). Stentless bioprostheses had a longer median time to failure and failed more commonly with predominant regurgitation (11 vs. 9 years, p¼0.02 and 58.9% vs. 21.8% in stented, p< 0.001), were larger (23.8 AE 2.1 vs. 23.0 AE 2.1 in stented, p¼0.002) and had lower degree of stenosis in comparison with stented: valve area 1.28 AE 0.62cm2 vs. 0.88 AE 0.43cm2, mean gradient 48 AE 28.6 mmHg vs. 64.7 AE 26.8mmHg, respectively; p< 0.001 for both). Stentless bioprostheses were more commonly treated by a CoreValve (65.1% vs. 34.7% SAPIEN, p< 0.001) and TEE was utilized more during these procedures (75.2% vs. 62.6% in stented, p¼0.01). Device malposition was more common in stentless and Mosaic stented valves (16.1%, 14.0% vs. 9.0% in non-Mosaic stented valves, p¼0.03). Coronary occlusion was more common in stentless bioprostheses (5.4% vs. 1.4% in stented, respectively, p¼0.01). Post procedural mean aortic valve gradient was lower post stentless VinV procedures (11.7 AE 7.2mmHg vs. 16.9 AE 9.1mmHg in stented, p< 0.001). Thirty-day and 1-year mortality rates were similar, when comparing stented and stentless procedures: 8.9% vs.6.6% (p¼0.39), 17.9% vs. 16.6% (p¼0.68), respectively. Conclusions: Aortic VinV implantation inside stentless bioprosthesis is challenging and associated with more device malposition and coronary occlusion events. Nevertheless, VinV procedures performed in stentless bioprostheses resulted better valve hemodynamics than in stented surgical valves and patient survival was similar. Background: It is important to elucidate factors that are associated with a poor outcome after transcatheter aortic valve replacement (TAVR) to improve patient selection. Tricuspid regurgitation (TR) and right ventricular dysfunction (RVD) adversely affect outcomes in patients with heart failure or mitral valve disease, but their impact on outcomes in patients with severe aortic stenosis (AS) treated with TAVR has not been well characterized. Methods: Patients enrolled and treated in the PARTNER II trial (inoperable cohort) (n¼553) were included and stratified according to the presence and severity of TR and RVD (qualitatively measured) on the baseline (pre-TAVR) echocardiogram as determined by a core lab. Multivariable Cox PH models were used to evaluate the association between TR and RVD and 1-year all-cause death. Results: TR severity and RV function were measured in 507 and 488 patients, respectively. Patients with none/trace (n¼167), mild (n¼205), moderate (n¼117), and severe (n¼18) TR had 1-year all-cause death rates of 16.9%, 17.2%, 32.6%, and 61.1%, respectively (p< 0.001). Patients with normal RV function (n¼335) and mild (n¼110) or moderate/severe RVD (n¼39) had 1 year all-cause death rates of 19.0%, 25.5%, and 38.5%, respectively (p< 0.001). Increasing severity of TR (p¼0.003) and RVD (p¼0.01) were also associated with increased re-hospitalization rates at 1 year. After adjusting for age, sex, BMI, STS score, prior infarct, prior CABG, frailty, permanent pacemaker, atrial fibrillation, left ventricular ejection fraction, aortic transvalvular mean gradient, and mitral regurgitation, moderate/severe TR was associated with increased 1-year mortality (adjusted HR 1.73, 95% CI 1.09-2.75, p¼0.01), whereas RVD was not (p¼0.67). Conclusions: In very high risk patients with severe symptomatic AS undergoing TAVR, moderate or severe TR is independently associated with increased 1-year mortality whereas RVD was only associated with mortality in univariable analysis. This may have implications for treatment decisions, including assessment of anticipated benefit from TAVR and whether concomitant surgical treatment of TR should be considered in operable patients.
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